Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;18(11):1015–27. https://doi.org/10.1056/NEJMoa2031893.
Franchini M, Corsini F, Focosi D, Cruciani M. Safety and Efficacy of Convalescent plasma in COVID-19: an overview of systematic reviews. Diagnostics (Basel). 2021;11(9). https://doi.org/10.3390/diagnostics11091663.
Kimber C, Lamikanra AA, Geneen LJ, et al. A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfus Med. 2023;33(1):26–38. https://doi.org/10.1111/tme.12942.
Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):115–26. https://doi.org/10.1001/jamainternmed.2021.6850.
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;29(10289):2049–59. https://doi.org/10.1016/s0140-6736(21)00897-7.
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;18(7):619–29. https://doi.org/10.1056/NEJMoa2031304.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;22:m3939. https://doi.org/10.1136/bmj.m3939.
O’Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;1(13). https://doi.org/10.1172/jci150646.
Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;15(24). https://doi.org/10.1172/jci155114.
Belov A, Huang Y, Villa CH, et al. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol. 2022;97(6):770–9. https://doi.org/10.1002/ajh.26531.
Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;18(7):610–8. https://doi.org/10.1056/NEJMoa2033700.
Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022;386(18):1700–11. https://doi.org/10.1056/NEJMoa2119657.
Levine AC, Fukuta Y, Huaman MA, et al. Coronavirus disease 2019 Convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 randomized trials. Clin Infect Dis. 2023;16(12):2077–86. https://doi.org/10.1093/cid/ciad088.
Focosi D, Franchini M, Pirofski LA, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022;21(3):e0020021. https://doi.org/10.1128/cmr.00200-21.
Rojas M, Rodríguez Y, Hernández JC, et al. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infect Dis. 2022;27(1):575. https://doi.org/10.1186/s12879-022-07560-7.
Misset B, Piagnerelli M, Hoste E, et al. Convalescent plasma for Covid-19-Induced ARDS in mechanically ventilated patients. N Engl J Med. 2023;26(17):1590–600. https://doi.org/10.1056/NEJMoa2209502.
Casadevall A, Pirofski LA. Misinterpretation of clinical research findings and COVID-19 mortality. Ann Intern Med. 2023;176(7):993–4. https://doi.org/10.7326/m23-0737.
Troxel AB, Petkova E, Goldfeld K, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a Meta-analysis. JAMA Netw Open. 2022;4(1):e2147331. https://doi.org/10.1001/jamanetworkopen.2021.47331.
Goldfeld KS, Wu D, Tarpey T, et al. Prospective individual patient data meta-analysis: evaluating convalescent plasma for COVID-19. Stat Med. 2021;30(24):5131–51. https://doi.org/10.1002/sim.9115.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-197. https://doi.org/10.1016/s1473-3099(20)30483-7.
Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022;4(1):e2147375. https://doi.org/10.1001/jamanetworkopen.2021.47375.
Jorda A, Kussmann M, Kolenchery N, et al. Convalescent plasma treatment in patients with Covid-19: a systematic review and Meta-analysis. Front Immunol. 2022;13:817829. https://doi.org/10.3389/fimmu.2022.817829
Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of Coronavirus Disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021;191(1):90–107. https://doi.org/10.1016/j.ajpath.2020.10.008.
Casadevall A, Pirofski LA, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio. 2021;12(2):e03372-20. https://doi.org/10.1128/mBio.03372-20.
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;17(8):599–609. https://doi.org/10.7326/0003-4819-145-8-200610170-00139.
Stadler E, Chai KL, Schlub TE, et al. Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis. Lancet Microbe. 2023;4(11):e883-892. https://doi.org/10.1016/s2666-5247(23)00194-5.
Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;3(1):e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647.
Herman JD, Wang C, Loos C, et al. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nat Commun. 2021;25(1):6853. https://doi.org/10.1038/s41467-021-27201-y.
Herman JD, Wang C, Burke JS, et al. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. Cell Rep Med. 2022;15(11):100811. https://doi.org/10.1016/j.xcrm.2022.100811.
Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020;1(12):6728–38. https://doi.org/10.1172/jci141206.
Askenase PW. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: do the exosomes in convalescent plasma antagonize the weak immune antibodies? J Extracell Vesicles. 2020;10(1):e12004. https://doi.org/10.1002/jev2.12004.
Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol. 2003;170(7):3621–30. https://doi.org/10.4049/jimmunol.170.7.3621.
Goodner K, Horsfall FL. The protective action of type I antipneumococcus serum in mice: IV. The prozone. J Exp Med. 1936;31(3):369–75. https://doi.org/10.1084/jem.64.3.369.
Senefeld JW, Casadevall A, Joyner MJ. Convalescent plasma to deliver therapeutic antibodies against COVID-19. Trends Mol Med. 2022;28(5):435–6. https://doi.org/10.1016/j.molmed.2022.02.005.
Moog R. COVID 19 convalescent plasma: Is there still a place for CCP? Transfus Apher Sci. 2023;62(2):103680. https://doi.org/10.1016/j.transci.2023.103680.
Farnsworth CW, Case JB, Hock K, et al. Assessment of serological assays for identifying high titer convalescent plasma. Transfusion. 2021;61(9):2658–67. https://doi.org/10.1111/trf.16580.
Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61(3):275–91. https://doi.org/10.1016/s0009-9236(97)90160-0.